DR. CHEUNG WONG, M.D.
Medical Practice at Colchester Ave, Burlington, VT

License number
Vermont 042-000-9968
Category
Medical Practice
Type
Obstetrics & Gynecology
License number
Vermont 042-000-9968
Category
Medical Practice
Type
Gynecologic Oncology
Address
Address
111 Colchester Ave, Burlington, VT 05401
Phone
(802) 847-3919
(802) 863-7901

Personal information

See more information about CHEUNG WONG at radaris.com
Name
Address
Phone
Cheung Wong, age 58
8 Brownell Way, South Burlington, VT 05403

Organization information

See more information about CHEUNG WONG at bizstanding.com

Cheung Wong MD

111 Colchester Ave, Burlington, VT 05401

Industry:
Oncology, Surgeons, Obgyn
Phone:
(802) 847-5110 (Phone)
Cheung Wong

Professional information

Cheung Wong Photo 1

Dr. Cheung Wong, Burlington VT - MD (Doctor of Medicine)

Specialties:
Gynecologic Oncology
Address:
111 Colchester Ave SUITE ACCMP4, Burlington 05401
(802) 847-5110 (Phone)
Certifications:
Gynecological Oncology, 2010, Obstetrics & Gynecology, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
111 Colchester Ave SUITE ACCMP4, Burlington 05401
Fanny Allen Hospital
101 College Pkwy, Colchester 05446
Rutland Regional Medical Center
160 Allen St, Rutland 05701
Education:
Medical School
New York University School Of Medicine
Graduated: 1992
Mt Sinai Mc
Graduated: 1996
Roswell Park Cancer Institute


Cheung Wong Photo 2

Cheung Wong, Burlington VT

Specialties:
Obstetrics & Gynecology, Gynecologic Oncology, Surgery
Work:
Fletcher Allen Health Care
111 Colchester Ave, Burlington, VT 05401
Education:
New York University (1992)


Cheung Wong Photo 3

Use Of Erythropoietin For Treatment Of Cancer

US Patent:
2005026, Dec 1, 2005
Filed:
Mar 28, 2005
Appl. No.:
11/093177
Inventors:
Karen Lounsbury - Essex Junction VT, US
Cheung Wong - South Burlington VT, US
Sarah Hale - Essex Junction VT, US
International Classification:
A61K038/18
US Classification:
514012000
Abstract:
A method for treating cancer is provided. The method involves administering to subjects in need of such treatment an effective amount of erythropoietin of an analog thereof effective to inhibit angiogenesis in a tumor. Also provided are methods to reduce HIF-1α protein levels and/or VEGF expression, particularly in tumors.